Journal of Clinical Apheresis · 2001 · 37 citations · 9 references
MedicineInfectious DiseasesPharmacologyClinical NutritionClinical PharmacologyLipid BiochemistryAntiretroviral TherapyDyslipidemia ManagementHuman Immunodeficiency Virus PharmacotherapyLipid DisordersPancreatic DiseasesPancreatic DisordersHyperlipidemia TreatmentHyperlipidemic PancreatitisPancreatic Enzyme TestingPancreatic Enzyme TherapyPancreatic Lipase ActionProtease Inhibitors
The use of protease inhibitors such as ritonavir to treat HIV-infected individuals has been associated with lipodystrophy, combined hyperlipidemias, and hypertriglyceridemia-induced pancreatitis. We report here on the treatment by plasmapheresis of a HIV-patient who presented with a rapid onset of severe ritonavir-induced hypertriglyceridemia complicated with an acute pancreatitis. A 35-year-old HIV-1 positive male following 3 weeks of ritonavir treatment presented with nausea, abdominal pain, a distended abdomen, and the following laboratory values: amylase (238 U/L), lipase (864 U/L), total cholesterol (27.1 mmol/L), and triglycerides (62.9 mmol/L). Following two plasmaphereses, the levels of total cholesterol, triglycerides, lipase, and amylase declined drastically and the patient was discharged home after 4 days with lipid and pancreatic enzyme levels within the reference range. To our knowledge, this is the first case of pancreatitis due to a PI-induced hyperlipidemia in a HIV-patient treated with plasmapheresis in an acute setting.
9
Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors
Daniel Périard, Amalio Telenti, Philippe Sudre et al. · Circulation · 1999 · 610 citations
Marked hyperlipidaemia on ritonavir therapy.
Arlene Sullivan, Matthew R. Nelson · PubMed · 1997 · 110 citations